Connect with us

Technology

Starpax Biopharma Never-Before-Seen Magnetodrones™ and PolarTrak® Technology Transform Cancer Treatment

Published

on

New 27,000-square-foot manufacturing facility now in operation to produce therapeutic Magnetodrones

MONTREAL, June 25, 2024 /PRNewswire/ — In a significant stride for cancer treatment, Starpax Biopharma Inc. (“Starpax”) today unveiled its Starpax Cancer Treatment Platform™, a groundbreaking innovation that marks a monumental achievement in the company’s journey towards pioneering new frontiers in cancer treatment. With a 100% remission rate and no side effects in all the subjects of the company’s preclinical trials, this technology is conceived to address all solid tumors, representing 90% of cancer and 89% of deaths.

The Starpax technology is addressing a major resistance problem to treatment that chemotherapy and immunotherapy haven’t solved for over a century. Studies have demonstrated that 90% of the volume of a tumor receives little or no drug at all. Drugs or immune cells don’t swim; they need blood vessels to be distributed in a tumor and reach cancer cells, yet blood vessels and lymphatics in a tumor become chaotic, malfunctioning, or collapse. More studies have also demonstrated that as little as 1% of the dose of systemic chemotherapy, such as nanocarriers, antibodies, and precision target drugs, reach a tumor, leaving 99% of the toxic doses free to circulate in the patient’s body, attacking healthy organs and creating unwanted side effects.

The Starpax Magnetodrones™ are the first component of the Starpax Cancer Treatment Platform™. They are living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields. They are injected directly into a tumor and can swim in tumors without using blood vessels or circulating in the bloodstream.

The Starpax PolarTrak® is the second component of the platform. It is a proprietary medical device in which the patient is installed. It generates unique magnetic fields to keep the Magnetodrones captive inside the tumor, preventing them from escaping into the rest of the patient’s body and forces the Magnetodrones to spread throughout the whole volume of the tumor, including in hypoxic zones where the cancerous stem cells are located. The process is managed by the Polartrak artificial intelligence, based on the data of the patient’s tumor taken from the MRI imagery scanner days before the treatment. Magnetodrones have faced over 800 mutations in the laboratory and therefore are able to detect low levels of oxygen in the tumor’s hypoxia areas where the stem cells are located. Then, they penetrate and accumulate in these areas to introduce the anticancer therapeutic. 

“Our breakthrough Starpax platform can save countless lives, offering new hope in the fight against cancer,” said Michael Gareau, Founding President of Starpax. “The unveiling of the Starpax Magnetodrones and PolarTrak lays the foundation for the future of cancer treatment. These technologies are not merely company milestones but keystones in developing solutions that completely transform the way we treat cancer today.”

Direct delivery and spread of anticancer therapeutics into tumors increases efficacy and minimizes damage to healthy tissues. Compared to modern systemic treatments, Starpax’s technology allows the administration of up to 50 times more drug directly in the tumor, including hard-to-reach hypoxic zones. By focusing treatment specifically on the tumor, Starpax’s technology significantly lowers the risk of adverse effects. It allows 800 times fewer toxic molecules to be introduced into the body than standard chemotherapy treatments, drastically reducing toxicity and side effects. The two-part platform of Magnetodrones and PolarTrak creates a safer, more effective alternative to traditional treatments, promising a significant leap in patient care and recovery.

Dr. Gerald Batist, Director of Segal Cancer Center at Jewish General Hospital, stated, “Finally, with the Starpax technology, we have bacteria that actually move towards and can be accumulated in the hypoxic zone. This represents a big step in responding to a challenge that has been there and persists resistance to treatment.”

To manufacture the Starpax Magnetrodrones, the company has also announced its new facility in Montreal is now in operation. When fully operational, the 27,000-square-foot facility has the capacity to produce Magnetodrones to treat 10,000 patients annually. A second Magnetodrones manufacturing plant is being discussed, with a capacity of 110,000 patients annually.

Starting with two patents in 2017, Starpax now holds 57 key patents and pending patents for its Magnetodrones and PolarTrak, as well as the interventional procedure ensuring a competitive edge in the field. Since its founding, Starpax has collaborated with top cancer research institutions, including McGill University, Jewish General Hospital, Polytechnique Montréal, and TransMedTech Institute. In September 2023, the company announced a $24 million Regulation A+ capital raise. It will begin clinical trials in 2025.

About Starpax Biopharma Inc.
Starpax Biopharma Inc. is a biopharma tech company that unites four scientific disciplines: biochemistry, microbiology, electromagnetism engineering, and artificial intelligence to create a never-before-seen technology that is transforming cancer treatment. Its technology aims to overcome the major hurdles of systemic treatments and precisely reach cancer cells throughout tumors, including hypoxic zones, without circulating in the bloodstream, thereby avoiding side effects. To learn more, visit https://starpaxbiopharma.com.

Media Contact
Leigh Brandt
leigh@lightspeedpr.com

View original content:https://www.prnewswire.com/news-releases/starpax-biopharma-never-before-seen-magnetodrones-and-polartrak-technology-transform-cancer-treatment-302181096.html

SOURCE Starpax Biopharma, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

iMarketKorea Signs Two MOUs with Vietnam’s Phu Tho Provincial People’s Committee and BIDV

Published

on

By

Participates in Korea-Vietnam Economic Delegation

Accelerates development of an industrial park in Phu Tho Province near Hanoi, while attracting advanced manufacturing companies and building a supply chain ecosystemPlans parallel development of an Inland Container Depot (ICD) to strengthen logistics competitivenessExpands discussions with Bank for Investment and Development of Vietnam (BIDV) on financial support measures and new business opportunities

HANOI, Vietnam and SEOUL, South Korea, April 27, 2026 /PRNewswire/ — iMarketKorea, a leading industrial materials distribution company led by CEO Kim Hak-jae, announced that it has signed two Memoranda of Understanding (MOUs) with the Phu Tho Provincial People’s Committee and Bank for Investment and Development of Vietnam during the MOU signing session at the Korea-Vietnam Business Forum, hosted by Korea’s Ministry of Trade, Industry and Energy and the Korea Chamber of Commerce and Industry. The company participated in the official Korea-Vietnam economic delegation.

As Vietnam’s investment environment continues to advance, cooperation in production infrastructure such as industrial parks has become increasingly important. Based on prior discussions with Phu Tho Province, iMarketKorea formalized this partnership through the latest agreements.

Located near Noi Bai International Airport, Phu Tho Province is emerging as a strategic logistics hub and an attractive production base for global companies. The province recorded 10.52% gross regional domestic product (GRDP) growth in 2025, ranking fourth among Vietnam’s provinces.

Through the agreement, iMarketKorea plans to develop a national industrial park in Phu Tho Province and actively attract global manufacturing companies. The company also aims to build a supply chain-driven industrial ecosystem by strengthening collaboration among related businesses centered around the industrial complex.

To enhance logistics competitiveness, iMarketKorea will also pursue the development of an Inland Container Depot (ICD) with bonded warehousing functions. An ICD is an inland logistics hub enabling customs clearance and cargo handling. When integrated with the industrial park, it is expected to improve import-export efficiency and strengthen the region’s attractiveness to manufacturers.

Kim Hak-jae, CEO of iMarketKorea, said, “This agreement establishes the foundation for integrated production and logistics infrastructure. Through cooperation with the Phu Tho provincial government and BIDV, we plan to establish a one-stop support system covering administration, finance, legal matters, and taxation. We will also create an environment where high-tech parts and materials companies can effectively utilize local incentives and gradually expand future cooperation.”

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/imarketkorea-signs-two-mous-with-vietnams-phu-tho-provincial-peoples-committee-and-bidv-302753801.html

SOURCE iMarketKorea

Continue Reading

Technology

Global Customers Are Taking a Closer Look at Focused Photonics Inc.

Published

on

By

HANGZHOU, China, April 24, 2026 /PRNewswire/ — For scientific instrument companies competing globally, differentiation increasingly depends on more than product specifications alone. Customers are looking beyond performance claims to assess whether a company can consistently translate technology into manufacturable products, proven applications, reliable delivery and long-term service support.

That shift was evident during Focused Photonics Inc.’s (FPI) Global Customer Experience Day 2026 in Hangzhou, where customers and partners from dozens of countries visited the company’s Qingshanhu Innovation Base, headquarters and live application sites. For many attendees, the event offered a closer look at how a China-headquartered scientific instrument company is building capabilities across R&D, manufacturing, systems integration and lifecycle support.

At Qingshanhu Innovation Base, visitors saw key stages of FPI’s operations firsthand, including engineering, precision manufacturing, system integration, testing and service readiness. For many international customers, these visits are less about viewing a production line and more about assessing execution: whether a supplier has the engineering discipline, manufacturing depth and support infrastructure required to deliver consistently in real operating environments.

This is becoming increasingly important across the industry. As customer expectations evolve, competition is moving beyond stand-alone instrument performance toward integrated solutions, automation, data integrity, compliance and lifecycle value. In industrial and environmental applications in particular, uptime, stability and workflow fit often matter as much as analytical capability.

At its global customer conference, FPI outlined how it is responding to that transition, highlighting continued investment across environmental monitoring, industrial process analysis, laboratory analysis and life science applications. The company is also expanding the role of digitalization, automation and AI to improve application readiness and solution delivery.

Application-focused exchanges during the event reinforced the same point. In discussions on environmental, industrial and laboratory scenarios, customers focused not only on performance metrics, but also on regulatory fit, workflow integration, long-term operation under complex conditions, and the ability of solutions to function reliably once deployed. These are increasingly central criteria in global purchasing decisions.

The clearest proof came from real-world settings. At the Hangzhou Ecological Environment Monitoring Center, visitors saw FPI’s automated water quality laboratory in operation, where sample handling, workflow continuity and data generation are integrated into day-to-day use. For customers, this offered a more concrete view of how a solution performs not just in demonstration, but in routine operation.

Taken together, the event underscored a broader industry reality: global competition in scientific instruments is increasingly defined not only by what a product can do, but by whether a company can manufacture it at scale, deploy it effectively, support it locally and sustain performance over time. That broader operational capability is becoming a decisive part of how international customers evaluate suppliers.

View original content:https://www.prnewswire.com/news-releases/global-customers-are-taking-a-closer-look-at-focused-photonics-inc-302753822.html

SOURCE Focused Photonics Inc.

Continue Reading

Technology

Straits Financial Services Pte Ltd Granted Overseas Intermediary Futures Broker Status by Shanghai Futures Exchange and Guangzhou Futures Exchange

Published

on

By

SINGAPORE, April 27, 2026 /PRNewswire/ — Straits Financial Services Pte Ltd (“SFSPL”), a member of Straits Financial Group, is pleased to announce that it has been granted overseas intermediary (OI) futures broker status by the Shanghai Futures Exchange (SHFE) and the Guangzhou Futures Exchange (GFEX).

This recognition marks an important milestone in expanding international access to China’s futures markets and further strengthens SFSPL’s ability to connect global investors with onshore opportunities.

As an overseas intermediary futures broker, SFSPL will be able to facilitate client access to selected products listed on SHFE and GFEX. The overseas intermediary model significantly lowers barriers to entry for international participants by removing the need for complex onshore structures and enabling more efficient cross-border access, while operating within China’s regulated market environment.

“As China’s futures market continues to open up, this recognition represents a meaningful milestone for both SFSPL and our clients,” said Roger Quek, Chief Executive Officer and Managing Director, Straits Financial Services Pte Ltd. “We are pleased to support international investors with more seamless access to China’s onshore derivatives market, while maintaining a strong focus on risk management, compliance, and execution efficiency.”

As China’s derivatives market continue to evolve, SFSPL is strongly positioned to support clients looking to deepen their involvement in this high-potential market.

SFSPL remains committed to delivering robust trading capabilities, seamless market access, and trusted expertise to help clients navigate global investment opportunities.

About Straits Financial Services Pte Ltd

At Straits Financial Services Pte Ltd, we distinguish ourselves by promoting key and innovative contracts to support the financial and commodity derivative markets as well as providing products and services to fulfill the needs of every trader.

With a strong presence in Asia and a deep understanding of the global markets, we provide value to our clients by enabling global access with a local perspective. Established in 2010, Straits Financial Services Pte Ltd is part of Straits Financial Group which is headquartered in Singapore.

Straits Financial Services Pte Ltd provides a fully-integrated service for our clients to access the financial and commodity derivative markets and we strive to build lasting relationships with our clients.

For more information, please visit our website at https://www.straitsfinancial.com.

This document is issued for information purposes only. This document is not intended and should not under any circumstances to be construed as an offer or solicitation to buy or sell, nor financial advice or recommendation in relation to any capital market product. All the information contained herein is based on publicly available information and has been obtained from sources that Straits Financial Services Pte Ltd believes to be reliable and correct at the time of publishing this document.

Straits Financial Services Pte Ltd will not be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information. Past performance or historical record of futures contracts, derivatives contracts, and commodities is not indicative of the future performance. The information in this document is subject to change without notice.

If after reading the foregoing content you have any doubts in relation thereto, please consult your own independent legal, financial and/or professional adviser.

View original content:https://www.prnewswire.com/apac/news-releases/straits-financial-services-pte-ltd-granted-overseas-intermediary-futures-broker-status-by-shanghai-futures-exchange-and-guangzhou-futures-exchange-302752994.html

SOURCE Straits Financial

Continue Reading

Trending